文献速递乳腺MR

机器学习联合磁共振成像预测乳腺癌新辅助化疗反应:系统评价与Meta分析

Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
PubMed 文献 · Eur J Radiol · 2022-03-10

本Meta分析纳入17项研究共3392例患者,评估机器学习联合MRI预测乳腺癌新辅助化疗病理反应的诊断准确性。机器学习联合MRI的汇总AUC为0.87(95%CI 0.84-0.91);亚组分析中深度学习亚组AUC为0.92(95%CI 0.88-0.97),高于机器学习联合影像组学亚组的0.85(95%CI 0.82-0.90)(P=0.030);机器学习联合影像组学亚组中,MRI联合其他参数(临床或组织病理信息)的AUC为0.90(95%CI 0.85-0.96),优于仅用MRI参数的0.82(95%CI 0.78-0.86)(P=0.009)。

要点

  • 机器学习联合MRI预测乳腺癌新辅助化疗病理反应汇总AUC为0.87(95%CI 0.84-0.91)。
  • 深度学习亚组AUC 0.92(95%CI 0.88-0.97)高于机器学习联合影像组学亚组0.85(95%CI 0.82-0.90)(P=0.030)。
  • 机器学习联合影像组学亚组中,MRI联合其他参数AUC 0.90(95%CI 0.85-0.96)优于仅用MRI参数0.82(95%CI 0.78-0.86)(P=0.009)。

核心结论

  • 机器学习应用于MRI对预测乳腺癌患者新辅助治疗病理反应具有中等准确性;深度学习较机器学习联合影像组学具有更高的预测准确性。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE和EMBASE数据库截至2021年12月20日的文献,纳入17项研究共3392例患者,采用诊断准确性研究质量评价-2标准评估研究质量,以I2值评估异质性并决定采用随机效应模型,PROSPERO注册号CRD42022284071。

诊断标准与关键数值

  • 机器学习联合MRI预测新辅助治疗反应的汇总AUC为0.87(95%CI 0.84-0.91)。
  • 深度学习亚组AUC为0.92(95%CI 0.88-0.97),高于机器学习联合影像组学亚组AUC 0.85(95%CI 0.82-0.90)(P=0.030)。
  • 机器学习联合影像组学亚组中,MRI联合其他参数(临床或组织病理信息)AUC为0.90(95%CI 0.85-0.96),优于仅用MRI参数AUC 0.82(95%CI 0.78-0.86)(P=0.009)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this meta-analysis was to determine the diagnostic accuracy of machine learning (ML) models with MRI in predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer. Furthermore, we compared the pathologic complete response (pCR) prediction performance of ML + radiomics with that of a deep learning (DL) algorithm.

METHODS: A search for relevant studies published until December 20, 2021 was conducted in MEDLINE and EMBASE databases. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies -2 criteria. The I2 value assessed the heterogeneity of the included studies as well as the decision to adopt a random effects model. The area under the receiver operating characteristic curves (AUC) was pooled to quantify the predictive accuracy. Subgroup analysis, meta-regression analysis, and sensitivity analysis were performed to detect potential sources of study heterogeneity. A funnel plot was used to investigate publication bias. The PROSPERO ID of our study was CRD42022284071.

RESULT: Seventeen eligible studies encompassing 3392 patients were evaluated in the analysis. ML + MRI showed high accuracy (AUC = 0.87, 95% CI = 0.84-0.91) in predicting response to neoadjuvant therapy. In subgroup analysis, the AUC of the DL subgroup (AUC = 0.92, 95% CI = 0.88-0.97) was higher than that of the ML + radiomics subgroup (AUC = 0.85, 95% CI = 0.82-0.90) (P = 0.030). In the ML + radiomics subgroup, the studies using MRI combined with other parameters (clinical or histopathologic information; AUC = 0.90, 95% CI = 0.85-0.96) reported better performance than studies using only MRI parameters (AUC = 0.82, 95% CI = 0.78-0.86) (P = 0.009).

CONCLUSIONS: ML applied to MRI enabled moderate accuracy in predicting pathological response to neoadjuvant therapy in patients with breast cancer. Furthermore, the meta-analysis showed that DL had higher predictive accuracy than ML + radiomics.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Liang, Yu, Gao, et al. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. Eur J Radiol. 2022. PMID: 35290910. doi:10.1016/j.ejrad.2022.110247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。